Pharmacology and efficacy of vancomycin for staphylococcal infections in children.

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Vancomycin is effective against most multiply resistant staphylococci, organisms that are becoming increasingly important in clinical medicine. Reported experience with vancomycin therapy in pediatric patients is limited. In this study vancomycin was administered intravenously to 33 patients whose ages ranged from one week to 16 years and who had suspected or proved infections caused by either Staphylococcus aureus or Staphylococcus epidermidis. The spectrum of staphylococcal infections included skin and soft-tissue infections and abscesses, osteomyelitis, pneumonia, shunt infections, endocarditis, and septicemia. All 29 patients with bacteriologically proved staphylococcal infections responded to vancomycin therapy. Peak and trough concentrations of vancomycin in serum produced satisfactory bacteriostatic and bactericidal titers against the infecting pathogens. In an anephric patient hemodialysis removed only negligible amounts of vancomycin. The amount of vancomycin that penetrated into ventricular fluid of 10 patients with shunt infections ranged from 7% to 37% (mean, 18%) of serum concentrations. One case of phlebitis and one case of transient elevation of serum levels of aspartate amino transferase were observed. No renal or otologic damage was detected in any patient. Adequate dilution of the drug, intravenous administration during 1 hr, and monitoring of the concentration in serum of patients undergoing long-term treatment and/or with impaired renal function minimize the likelihood of side effects. Vancomycin is an effective and safe agent for treatment of staphylococcal infections in pediatric patients.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume3 suppl
StatePublished - Nov 1981

Fingerprint

Staphylococcal Infections
Vancomycin
Pharmacology
Serum
Staphylococcal Skin Infections
Infection
Pediatrics
Likelihood Functions
Kidney
Phlebitis
Soft Tissue Infections
Staphylococcus epidermidis
Clinical Medicine
Osteomyelitis
Therapeutics
Transferases
Endocarditis
Staphylococcus
Aspartic Acid
Intravenous Administration

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Pharmacology and efficacy of vancomycin for staphylococcal infections in children. / Schaad, U. B.; Nelson, J. D.; McCracken, G. H.

In: Reviews of Infectious Diseases, Vol. 3 suppl, 11.1981.

Research output: Contribution to journalArticle

@article{c6a17b4b5a9243979cd086eada1b038d,
title = "Pharmacology and efficacy of vancomycin for staphylococcal infections in children.",
abstract = "Vancomycin is effective against most multiply resistant staphylococci, organisms that are becoming increasingly important in clinical medicine. Reported experience with vancomycin therapy in pediatric patients is limited. In this study vancomycin was administered intravenously to 33 patients whose ages ranged from one week to 16 years and who had suspected or proved infections caused by either Staphylococcus aureus or Staphylococcus epidermidis. The spectrum of staphylococcal infections included skin and soft-tissue infections and abscesses, osteomyelitis, pneumonia, shunt infections, endocarditis, and septicemia. All 29 patients with bacteriologically proved staphylococcal infections responded to vancomycin therapy. Peak and trough concentrations of vancomycin in serum produced satisfactory bacteriostatic and bactericidal titers against the infecting pathogens. In an anephric patient hemodialysis removed only negligible amounts of vancomycin. The amount of vancomycin that penetrated into ventricular fluid of 10 patients with shunt infections ranged from 7{\%} to 37{\%} (mean, 18{\%}) of serum concentrations. One case of phlebitis and one case of transient elevation of serum levels of aspartate amino transferase were observed. No renal or otologic damage was detected in any patient. Adequate dilution of the drug, intravenous administration during 1 hr, and monitoring of the concentration in serum of patients undergoing long-term treatment and/or with impaired renal function minimize the likelihood of side effects. Vancomycin is an effective and safe agent for treatment of staphylococcal infections in pediatric patients.",
author = "Schaad, {U. B.} and Nelson, {J. D.} and McCracken, {G. H.}",
year = "1981",
month = "11",
language = "English (US)",
volume = "3 suppl",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Pharmacology and efficacy of vancomycin for staphylococcal infections in children.

AU - Schaad, U. B.

AU - Nelson, J. D.

AU - McCracken, G. H.

PY - 1981/11

Y1 - 1981/11

N2 - Vancomycin is effective against most multiply resistant staphylococci, organisms that are becoming increasingly important in clinical medicine. Reported experience with vancomycin therapy in pediatric patients is limited. In this study vancomycin was administered intravenously to 33 patients whose ages ranged from one week to 16 years and who had suspected or proved infections caused by either Staphylococcus aureus or Staphylococcus epidermidis. The spectrum of staphylococcal infections included skin and soft-tissue infections and abscesses, osteomyelitis, pneumonia, shunt infections, endocarditis, and septicemia. All 29 patients with bacteriologically proved staphylococcal infections responded to vancomycin therapy. Peak and trough concentrations of vancomycin in serum produced satisfactory bacteriostatic and bactericidal titers against the infecting pathogens. In an anephric patient hemodialysis removed only negligible amounts of vancomycin. The amount of vancomycin that penetrated into ventricular fluid of 10 patients with shunt infections ranged from 7% to 37% (mean, 18%) of serum concentrations. One case of phlebitis and one case of transient elevation of serum levels of aspartate amino transferase were observed. No renal or otologic damage was detected in any patient. Adequate dilution of the drug, intravenous administration during 1 hr, and monitoring of the concentration in serum of patients undergoing long-term treatment and/or with impaired renal function minimize the likelihood of side effects. Vancomycin is an effective and safe agent for treatment of staphylococcal infections in pediatric patients.

AB - Vancomycin is effective against most multiply resistant staphylococci, organisms that are becoming increasingly important in clinical medicine. Reported experience with vancomycin therapy in pediatric patients is limited. In this study vancomycin was administered intravenously to 33 patients whose ages ranged from one week to 16 years and who had suspected or proved infections caused by either Staphylococcus aureus or Staphylococcus epidermidis. The spectrum of staphylococcal infections included skin and soft-tissue infections and abscesses, osteomyelitis, pneumonia, shunt infections, endocarditis, and septicemia. All 29 patients with bacteriologically proved staphylococcal infections responded to vancomycin therapy. Peak and trough concentrations of vancomycin in serum produced satisfactory bacteriostatic and bactericidal titers against the infecting pathogens. In an anephric patient hemodialysis removed only negligible amounts of vancomycin. The amount of vancomycin that penetrated into ventricular fluid of 10 patients with shunt infections ranged from 7% to 37% (mean, 18%) of serum concentrations. One case of phlebitis and one case of transient elevation of serum levels of aspartate amino transferase were observed. No renal or otologic damage was detected in any patient. Adequate dilution of the drug, intravenous administration during 1 hr, and monitoring of the concentration in serum of patients undergoing long-term treatment and/or with impaired renal function minimize the likelihood of side effects. Vancomycin is an effective and safe agent for treatment of staphylococcal infections in pediatric patients.

UR - http://www.scopus.com/inward/record.url?scp=0019638517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019638517&partnerID=8YFLogxK

M3 - Article

C2 - 7342292

AN - SCOPUS:0019638517

VL - 3 suppl

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

ER -